A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the "Back of the Line" as a therapy for dyslipidemia?

Journal of Clinical Lipidology

Volumn 2, Issue 5, 2008, Pages 313-317

  Toth, Peter P ^a   Maki, Kevin C ^b  

^a Sterling Rock Falls Clinic ^*  (United States)

^b Provident Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; ROFECOXIB; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ALDOSTERONE BLOOD LEVEL; ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; CAROTID ARTERY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEART LEFT VENTRICLE MASS; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 53449101871     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.06.011     Document Type: Editorial

References (29)

1. Brown B.G., and Taylor A.J. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe. N Engl J Med 358 (2008) 1504-1506
2. Drazen JM, Jarcho JA, Morissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med. 358:1507-1508.
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
5. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
6. National Lipid Association Statement on ENHANCE study findings: Premature judgment unwarranted. http://www.lipid.org/press/index.php Accessed May 19, 2008
7. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., et al., Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
8. Abate N., Catapano A.L., Ballantyne C.M., Davidson M.H., et al. Effect of ezetimibe/simvastain versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. J Clin Lipidol 2 (2008) 91-105
9. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Gazzara R.A., Brady W.E., and Palmisano J. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 81 (2006) 1177-1185
10. Denke M., Pearson T., McBride P., Gazzara R.A., Brady W.E., and Tershakovec A.M. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 3 (2006) 93-102
11. Guyton J.R., Goldberg R.B., Mazzone T., et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol 2 (2008) 19-24
12. Jackevicius C.A., Tu J.V., Ross J.S., Ko D.T., and Krumholz H.M. Use of ezetimibe in the United States and Canada. N Engl J Med 358 (2008) 1819-1828
13. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 357 (2001) 577-581
14. Van Wissen S., Smilde T.J., Trip M.D., Stalenhoef A.F.H., and Kastelein J.J.P. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 95 (2005) 264-266
15. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEROR Trial. JAMA 297 (2007) 1344-1353
16. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
17. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness. ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
18. Luyer M.D.P., Khosla S., Owen W.G., and Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86 (2001) 3629-3634
19. Koh K.K., Shin M.-S., Sakuma I., et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 24 (2004) 1516-1521
20. Lewandowski K.C., Komorowski J., Mikhalidis D.P., et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 91 (2006) 3123-3130
21. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
22. Landmesser U., Bahlmann F., Mueller M., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
23. Fichtischerer S., Schmidt-Lucke C., Bojunga S., et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD; clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 27 (2006) 1182-1190
24. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?. A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
25. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
26. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
27. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., et al. Results of the National Cholesterol Education Program (NCEP) Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
28. Maki K.C., Galant R., and Davidson M.H. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 96 suppl (2005) 59K-64K
29. Howard B.V., Roman M.J., Devereux R.B., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS randomized trial. JAMA 299 (2008) 1678-1689